KORU Medical's Q4 2024: Discrepancies in Novel Therapies Revenue, Oncology Strategy, and Global Expansion Plans

These are the key contradictions discussed in KORU Medical Systems' latest 2024 Q4 earnings call, specifically including: Novel Therapies revenue variability and market growth expectations, Oncology opportunity and market assessment, and International expansion timelines:



Record Revenue and Market Growth:
- KORU Medical Systems reported $8.8 million in revenue for Q4 2024, representing a 23% increase over the prior year, with full-year revenues totaling $33.6 million, indicating an 18% year-on-year growth.
- The growth was driven by record-setting revenues and gross margin expansion, driven by increased market share capture in the U.S. market and international expansion.

International Expansion Success:
- KORU's international core business achieved 14% growth in Q4 and 32% for the full year, with significant contributions from new geographies in the Middle East, North Africa, and Eastern Europe.
- This growth was due to strong supply volumes and increased patient growth in existing markets, alongside strategic expansion into new regions.

Novel Therapies and Partnerships:
- Novel Therapies revenues demonstrated a 122% increase to $700,000 in Q4, with a 62% year-on-year growth.
- This growth was driven by increased collaborations with pharmaceutical companies and clinical trial product revenues, positioning KORU for further market expansion.

Strong Financial Performance and Operational Efficiency:
- For the full year, KORU achieved a gross margin of 63.4%, with significant operating expense management and positive cash flows in Q4.
- This financial performance was attributed to disciplined operating expense management, improved manufacturing productivity, and strategic investments in next-generation products.